Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PTC Therapeutics -- PTCT -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3)	1/24/2014 3:36:59 PM
From: scaram(o)uche	Respond to of 38

tweet from the CEO of RTRX..... Martin Shkreli ?@MartinShkreli 7h $PTCT should be ashamed of itself. press release says nothing of the fact the EMA rejected the drug because EMA doesn't think it works. Expand Collapse Reply Retweet Retweeted Delete Favorite Favorited More Embed Tweet Report Tweet (PTCT currently up a fraction on this bad news, RTRX is off 15%. Glass houses.) Best! Rick

To: tuck who wrote (3)	1/24/2014 3:52:41 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 38

XNCR, which has two CD123 shots on goal (presuming that that molecule from CSL.AX derived from the XNCR license, which I haven't been able to confirm), has taken a couple of shots to the chin earlier this week and is holding up on this down day. Lotsa lockup shares yet to come, but worth watching. Pseudo Biologist was once a consultant, to give you an idea of the quality of their research. In antibodies, it's not the size of the pipe but what you do with the Fc. Best! Rick